Buruli Ulcer (RICHARD PHILLIPS)

Head
Richard Odame Phillips,
Department of Medicine
School of Medical Sciences
KNUST, Kumasi
Tel. +233 244488555,
        +233 206300567,
        +233 209140451
Email: rodamephillips@gmail.com,
rop@africaonline.com.gh 

Staff

  1. Prof Ohene Adjei (Professor in Microbiology)
  2. Dr Stephen Fred Sarfo (MBChB, PhD, FWACP)
  3. Dr Elliot Tannor (MBChB)
  4. Dr Yaw Ampem Amoako (MBChB)
  5. Dr Lambert Appiah (MBChB)
  6. Mrs Dorcas Ohui Owusu (PhD student)
  7. Dr. Michael Frimpong (Postdoctoral fellow)
  8. Mr Daniel Antwi Berko (PhD student)
  9. Mrs Mabel Sarpong-Duah (M Phil student)
  10. Mr Aloysius D Loglo (MPhil student)
  11. Miss Letitia Kunaa (Laboratory Technologist)

Project descriptions
Buruli ulcer related ongoing projects

1. Research Title
Co-infection of M. tuberculosis or M ulcerans with Mansonella perstans in Ghana, Benin and Cameroun (Map2Co)

Date: 2013- 2016

Summary: The objectives of this study include:

• Epidemiology of current M. perstans infected individuals and vectors and associated prevalence of mycobacterial diseases
• Improvements in M. perstans/Wolbachia detection and establishment of a mouse model of M. perstans infection
• Characterize the influence of M. perstans co-infections on immunity and clinical picture of individuals with TB and BUD
• Determine influence of M. perstans infection and doxycycline treatment on host immunity against mycobacterial infection and disease susceptibility

Sponsor: German Research Foundation (DFG)

Collaborators:

  • Dr Ellis Owusu-Dabo KCCR-KNUST
  • Dr Alex Debrah KNUST

Co-Principal Investigators:

  • Prof. Dr. Marc Jacobsen, University of Duesseldorf, Germany
  • Prof. Dr. med. Achim Hoerauf, University of Bonn, Germany
  • Prof Samuel Wanji, University of Buea, Cameroun


2. Research Title:

Pathogenesis and management of M. ulcerans disease, Buruli ulcer (Buruli_Path)

Date: 2012 – 2017

Summary: The objectives of this study include:

  • To identify markers for a rapid response to antibiotic treatment of Mu disease
  • To identify predictive markers of paradoxical reactions in Mu disease
  • To investigate the pathogenesis of oedematous lesions in Mu disease

Sponsor: MRC/DfID UK

Co Principal Investigator:
• Mark Wansbrough-Jones,Division of Clinical Sciences, Infectious Diseases, St George’s, University of London

Collaborators:

  • Dr Caroline Demangel, Pasteur Institute Paris France
    – Hepatitis B and C related ongoing projects

3. Collaborative study with the University of Liverpool (HEPIK) and South Tees Hospital (Middlesbrough)


Research Title:
HIV and Hepatitis B virus co-infection; Antiviral therapy and drug resistance; HIV genetic variability.

Dates: 2010-2014

Summary:
Together with the University College of London I am accessing lamivudine-containing anti-HIV therapy. As lamivudine also has partial activity against hepatitis B, I am interested in exploring how drug pressure is influencing the genetic evolution of both HIV and hepatitis B virus, and ultimately clinical outcomes in these cohorts. Preliminary data show suboptimal suppression of hepatitis B replication, and evolution of both drug resistant mutants and other variants that carry a highly mutated hepatitis B surface antigen. These mutants represent a significant public health threat as they can escape recognition by diagnostic assays and vaccine-induced neutralising antibodies

Funding body: Leverhulme-Royal Society Africa award

Collaborators:
• Prof George Bedu-Addo

Co Principal Investigator:
• Prof Anna Maria Geretti, University of Liverpool, UK
• Dr David Chadwick, South Tees Hospital, (Middlesbrough)


4. Research Title:
Detection of Chronic HCV infection and recovery among a cohort of HCV positive blood donors in Kumasi.

Date 2013-14

Summary:
To compare HCV third generation EIA and RIBA assays results to the previously used HCV rapid screening test results. To develop criteria to define chronic infection and HCV recovery based on assay results that will be used in future studies.

Sponsor: Loyola University Medical Center

Co Principal Investigator:
• Jennifer Layden, Assistant Professor of Medicine and Public Health Sciences, Loyola University Medical Center, Chicago USA


– Scientific output 2013-14

  1. Chadwick D, Stanley A, Sarfo S, Appiah L, Ankcorn M, Foster G, Schwab U, Phillips R, Geretti AM.. Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa. AIDS. 2013 Jan 2;27(1):139-41.
  2. Fred S. Sarfo , Rosie Keegan , Lambert Appiah ,Shaid Shakoor , Richard Phillips, Betty Norman,Yasmin Hardy, George Bedu-Addo, Lydia Longstaff, David R.Chadwick High prevalence of renal dysfunction and association with risk of death amongst HIV-infected Ghanaians Journal of Infection (2013) 67, 43e50
  3. Feldt T, Sarfo FS, Zoufaly A, Phillips RO, Burchard G, van Lunzen J, et al. Hepatitis E virus infections in HIV-infected patients in Ghana and Cameroon. J Clin Virol. 2013 Sep;58(1):18-23.
  4. Sarfo, Fred; Yuan, Zhang; Egan, Deirdre; Appiah, Lambert; Phillips, Richard; Bedu-Addo, George; Sarfo, Maame; Khoo, Saye; Owen, Andrew Owen; Chadwick, David Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients 2014 Journal of antimicrobial chemotherapy J Antimicrob Chemother 2014;69:491-9.

5.Sarfo FS, Sarfo MA, Kasim A, Phillips R, Booth M, Chadwick D. Long-term effectiveness of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Ghana. J Antimicrob Chemother. 2014 ;69:254-61.

6. Yaw Amoako, Karsor Kollie, Kingsley Asiedu, Clement Lugala Peter Lasub, Alexandre Tiendrebeogo, Richard Phillips, Fred Sarfo, Kabiru Mohammed Abass, Julien Ake Buruli ulcer in Liberia Emerging infectious diseases. 2014 Mar;20(3).

7. Richard O. Phillips, Fred S. Sarfo , Mohammed K. Abass, Justice Abotsi , Tuah Wilson , Mark Forson, Yaw A. Amoako, William Thompson, Kingsley Asiedu, Mark Wansbrough-Jones Clinical and Bacteriological Efficacy of Combination of Rifampicin and Streptomycin for 2 weeks followed by Rifampicin and Clarithromycin for 6 weeks for treatment of Mycobacterium ulcerans disease Antimicrobial agents and chemotherapy. 2014 Feb;58(2):1161-6.

8. Moritz Jansson, Marcus Beissner, Richard Phillips, Kossi Badziklou, Ebekalisai Piten, Issaka Maman, FRED SARFO, Kristina Huber, Agata Rhomberg, Dominik Symank, Magdalena Wagner, Franz Wiedemann, Jörg Nitschke, Abiba Banla Kere, Karl-Heinz Herbinger, Ohene Adjei, Thomas Löscher, and Gisela Bretzel Molecular Determination of Rifampicin Resistance in Clinical Samples of Patients with Buruli Ulcer Disease: A Comparison of two Assays. Journal of clinical microbiology. 2014 Apr;52(4):1246-9.

9. Koen Vandelannoote, Kurt Jordaens, Pieter Bomans, Herwig Leirs, Lies Durnez, Dissou Affolabi, Ghislain Sopoh, Julia Aguiar, Delphin Phanzu, Kibadi Kapay, Sara Eyangoh, Louis Bayonne Manou, Richard Odame Phillips, Anthony Ablordey, Leen Rigouts, Françoise Portaels, Miriam Eddyani, and Bouke de Jong Insertion Element – SNP typing provides insights into the population structure and evolution of the genetically monomorphic pathogen Mycobacterium ulcerans in Africa. Applied and environmental microbiology. 2014 Feb;80(3):1197-209.

10. Heather Williamson, Richard Phillips, Stephen Sarfo, and Pamela Small Genetic Diversity of PCR–positive, culture-negative and culture-positive Mycobacterium ulcerans isolated from Buruli ulcer patients in Ghana PloS one. 2014;9(2):e88007.

11. Klis S, Stienstra Y, Phillips RO, Abass KM, Tuah W, van der Werf TS. Long Term Streptomycin Toxicity in the Treatment of Buruli Ulcer: Follow-up of Participants in the BURULICO Drug Trial. PLoS neglected tropical diseases. 2014 Mar;8(3):e2739.

12. Sarfo FS, Abass KM, Phillips, RO, Thompsen W, Frimpong M, Abotsi J, Asiedu K, Wansbrough-Jones M. A Severe Case of Buruli Ulcer Disease with Pleural Effusions” 2014 Plos NTD (accepted In press)

13. Richard O. Phillips, Fred S. Sarfo, Jordi Landier, Reid Oldenburg, Mark Wansbrough-Jones, Kabiru Abass, William Thompson, Mark Forson, Arnaud Fontanet, Fatoumata Niang, and Caroline Demangel Chronic inflammatory and metabolic disorders in Buruli ulcer disease Journal of infectious diseases (In press PLOS NTD 2014

14. Richard Odame Phillips, Michael Frimpong , Stephen Fred Sarfo, Birte Kretschmer , Marcus Beissner, Alexander Debrah , Yaw Ampem Amoako, Kabiru Mohammed Abass, William Thompson, Mabel Sarpong Duah, Justice Abotsi , Ohene Adjei, Bernhard Fleischer, Gisela Bretzel, Mark Wansbrough-Jones, Marc Jacobsen Co-infection with Mycobacterium ulcerans and Mansonella perstans among Buruli ulcer patients in Ghana Emerging Infectious Diseases 2013 (In press 2014)

15. Fred Stephen Sarfo, Richard Odame Phillips, Jihui Zhang, Mohammed K. Abass, Justice Abotsi, Yaw A. Amoako, Yaw Adu-Sarkodie, Clive Robinson, Mark H. Wansbrough-Jones Kinetics of mycolactone in human skin during antibiotic therapy for Mycobacterium ulcerans disease 2014 (In press, BMC infectious diseases)

16. Sandor K, van der Werf, TS, Phillips, R, Sarfo FS, Wansbrough-Jones, M, Y Stienstra Oral treatment for patients with Buruli ulcer co-infected with HIV: think twice 2014 volume 28 issue 5 p797-798

 

Kumasi Center for Collaborative Research in Tropical Medicine